Zobrazeno 1 - 10 of 201 pro vyhledávání: '"TOSHIHIKO MIZUTA"'
3
Akademický článek
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
Autor: Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa
Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in c
Externí odkaz: https://doaj.org/article/f5f37084f80443099bd5a4c15daea257
Zobrazit plný text záznamu
4
Akademický článek
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Autor: Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflammatory marker, we investigated rel
Externí odkaz: https://doaj.org/article/bc6dd35d26fe4df2aa0b662a99f00fd2
Zobrazit plný text záznamu
6
Akademický článek
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
Autor: Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis
Externí odkaz: https://doaj.org/article/eb35e2af95fa4d798ff5388601ac6ee0
Zobrazit plný text záznamu
7
Akademický článek
Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
Autor: Taiga Otsuka, Shunya Nakashita, Kimihiko Yanagita, Keisuke Ario, Hiroaki Kawasoe, Seiji Kawazoe, Yuichiro Eguchi, Toshihiko Mizuta
Publikováno v: Diseases, Vol 3, Iss 2, Pp 68-77 (2015)
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who
Externí odkaz: https://doaj.org/article/7915344b4090486b897d19ee9ffc3666
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje